Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

cts in clinical development or marketed products.

There can be no assurance that we will conduct additional CMV studies in the future. The FDA or other regulatory authorities may prohibit any future studies with maribavir or alternatively may require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval. There can be no guarantee that we will be successful in gaining regulatory approval of maribavir for any indications. The data that were submitted to the U.S. Food and Drug Administration includes data from two separate studies including the pivotal Phase 3 study of Cinryze in acute HAE attacks and the ongoing open-label study of Cinryze for acute treatment of HAE, which includes partial data from an ongoing open label study. The FDA may view the data regarding the use of Cinryze for acute treatment of HAE we have submitted as a supplemental BLA as insufficient or inconclusive, not accept our submission, request additional data, require additional clinical studies, delay any decision past the time frames anticipated by us, limit any approved indications, deny the approval of Cinryze for acute treatment of HAE or approve a competing product which has been granted orphan drug designation thereby preventing Cinryze from reaching the market for acute treatment of HAE. There can be no assurance that the FDA or EMEA will not require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval of any of our product candidates, or that we will be successful in gaining regulatory approval of any of our product candidates. Currently our market capitalization is less than our book value. As a result, we may be required to take a significant non-cash goodwill impairment charge and may be required to write off goodwill or other intangible assets in the future. If we are required to write off goodwill or other intangible assets, our financial position or resu
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... IN (PRWEB) August 22, 2014 The ... community and its members in Alaska that Alaska Governor ... Concurrent Resolution 15, further defining public use of Unmanned ... Systems Task Force. House Bill 255states that it is, ... to images captured by an unmanned aircraft system.” It ...
(Date:8/21/2014)... 21, 2014 DNA vaccine pioneer ... its development of JRC-LAMP-vax, an innovative and safe potential ... IC studies began this month in Hawaii, moving the ... , The Japanese red cedar releases pollen that causes ... Mountain Cedar pollen wreaks similar havoc in Colorado, New ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 His Majesty ... Opening , The Court of His Majesty Willem-Alexander, King ... attend the Grand Opening of POET-DSM Advanced Biofuels’ Project ... Sept. 3. , The King will take part in ... activity, scheduled for 11 a.m.-12:20 p.m. and tour the ...
(Date:8/21/2014)... 21, 2014 OTC Markets Group ... a biotechnology company, on its approval to list ... on OTCQX®, the best marketplace for established U.S. ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... execution of its growth strategy and achievement of ...
Breaking Biology Technology:State of Alaska Signs Unmanned Aircraft Systems Bill 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2
... CALGARY, Feb. 11 /PRNewswire-FirstCall/ - SemBioSys Genetics ... of therapeutic,proteins for metabolic and cardiovascular diseases, today ... of the Company, will be,presenting a corporate update ... on Wednesday, February 13, 2008 at the Waldorf ...
... Fla., Feb. 11 Further to Phlo,Corporation,s ("Phlo"") (OTC: ... Roll Out to Metropolitan New York City Account,Base," an ... distributor in Metropolitan New York City has sold and ... key account base,as part of such roll out. AQISS(TM) ...
... Feb. 11 Santaris Pharma, the,Danish biopharmaceutical company ... McCullagh, President and Chief Executive,Officer, will be presenting ... for,2008 at the Biotechnology Industry Organisation,s 10th Annual ... February 11th at 12:30 pm,US Eastern Standard Time ...
Cached Biology Technology:SemBioSys to present at the 10th Annual BIO CEO & Investor Conference 2Phlo Affiliate Reports Progress in New York City Metropolitan Area Roll-Out 2Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008 2
(Date:8/22/2014)... French . NAIROBI ... African soils looming as a major threat to food security ... over the last five years, 1.7 million African farmers in ... million hectares and helped them double or even triple crop ... Revolution in Africa (AGRA) focuses on intensive efforts initiated five ...
(Date:8/22/2014)... release is available in German . ... substances, in PCFs proteins are fixated in a way ... crystals. Next, the HZB and Fudan University researchers are ... as functional materials. Their findings are being published today ... 10.1038/ncomms5634). , Proteins are sensitive molecules. Everyone knows that ...
(Date:8/22/2014)... birds and the bees. But that old expression ... The fertilization process for flowering plants is particularly ... and female reproductive cells. New research from an ... and including Carnegie,s Wolf Frommer, David Ehrhardt, and ... process that guides flowering plant fertilization. It is ...
Breaking Biology News(10 mins):Effort to confront Africa's soil health crisis helps millions of farmers triple yields 2Effort to confront Africa's soil health crisis helps millions of farmers triple yields 3Effort to confront Africa's soil health crisis helps millions of farmers triple yields 4Proteins: New class of materials discovered 2Calcium and reproduction go together 2
... (Nov. 4, 2010) Columbia University Medical Center has ... in Cardiovascular Research, with the 2010 Lewis Katz Visiting ... renowned heart failure expert from University of Texas Southwestern ... winners of the 2010 Lewis Katz Cardiovascular Research Prize ...
... Nov. 4, 2010 BIO-key International, Inc. (OTC Bulletin ... biometric identification solutions, today announced plans to release third ...  In conjunction with the release, BIO-key has scheduled a ... Internet on Thursday, November 11, 2010 at 10:00 a.m. ...
... amount of water flowing in streams and rivers has ... that were assessed in a new nationwide USGS study. ... river ecosystems and loss of native species. ... to date of stream flow alteration," said Bill Werkheiser, ...
Cached Biology News:Columbia University Medical Center announces 2010 Katz Prizes in cardiovascular research 2Columbia University Medical Center announces 2010 Katz Prizes in cardiovascular research 3Columbia University Medical Center announces 2010 Katz Prizes in cardiovascular research 4Columbia University Medical Center announces 2010 Katz Prizes in cardiovascular research 5BIO-key® Announces Third Quarter 2010 Earnings Release and Conference Call Schedule 2Most river flows across the US are altered by land and water management 2
MagSi uniform silica particles coated with a carboxyl group containing polymer, covalently attached to the bead surface....
MAb to Vasopressin Preservative: NaN3...
Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
... glycoprotein. distributed in colon and rectum, ... lung and salivary gland tissues. ... and MUC2. Epitope: Tandem repeats ... MUC3 tandem repeat peptide Positive ...
Biology Products: